Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NHS England has announced a programme to provide NHS staff with evidence-based digital programmes to protect their mental health during the COVID-19 response. The apps are designed to help maintain healthy sleep, and reduce anxiety.

Sleepio is an automated digital self-help app based on cognitive behavioural therapy for insomnia. It was built by Colin Espie, Professor of Sleep Medicine at the Nuffield Department of Clinical Neurosciences and Co-Founder of digital therapeutics company Big Health. Subsequent research by Espie and his team has demonstrated the efficacy and safety of Sleepio, and provided a platform for recognition of the value of digital therapeutics more widely in the NHS and other workplaces internationally.

Fifteen NHS trusts and six GP practices have already rolled out access to Sleepio and Daylight, an app designed to help with worry and anxiety. These apps have now been made freely available to all NHS employees across the country in partnership with NHS England.

Professor Colin Espie has praised NHS England’s quick response in protecting the mental health of NHS staff as well as their physical health during the pandemic. He said: ‘I’m honoured that Big Health is able to support our colleagues in the NHS to help safeguard their mental health during these most challenging of times. NHS staff are working under enormous pressure while also experiencing significant changes to their lives at home as a result of COVID-19.’

To learn how to gain access to Daylight and Sleepio for your staff, please email ceo@bighealth.com

Similar stories

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Unique study of vascular disease reaches 20th anniversary

The only project of its kind anywhere that studies patients with all types of acute vascular events - including strokes, heart attacks, aneurysms - in order to develop better diagnostic tests and treatments celebrates its 20th anniversary this month.

New funding awarded to study persistent pain in inflammatory arthritis

The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.

Massive Publicity for Study of Effects of Mild COVID on Smell

Researchers from the University of Oxford have used data from UK Biobank participants to look at changes to the brain on average 4.5 months after mild SARS-CoV-2 infection.